“We have been unaware for some time of any therapies under development that come close to offering
an anti-cancer effect to anything like the same degree that we are seeing with NOX66, and in particular
delivering this level of benefit in a well-tolerated, minimally invasive and cost-effective manner. In the
context of what has been reported at ASCO 2020, the high response rates we are seeing with NOX66 in
both the DARRT and LuPIN programs mark NOX66 as a major drug prospect.”
Graham Kelly PhD, Noxopharm CEO and Executive Chairman
Ann: ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.015(12.0%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 11.0¢ | $45.44K | 375.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 629029 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 84087 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |